Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Compare COA-verified suppliers in the PepPal supplier directory and verify current vial size, concentration, and lab testing before any sourcing decision
"Compounding pharmacies who provide GLP-1 drugs -- and not just for weight loss but many other conditions -- can still do that but we're also making sure that bad actors -- grey and black markets -- who are deceptively advertising to patients, that it's FDA approved, that those folks are mandated that they cannot do that anymore." The bill would also make false or misleading claims about the compounded drugs a Deceptive Trade Practice
In obesity, GIP receptor activation is believed to contribute to the weight loss and metabolic effects observed with triple-agonist agents
Large phase 3 trials, including cardiovascular-outcome studies, are ongoing and had not reported results as of mid-2026 (ClinicalTrials.gov NCT05882045
